Article

FDA sets target date for completing OAB drug review

Astellas Pharma, Inc, has announced the receipt of a letter from the FDA indicating that it accepted for filing the new drug application for mirabegron (YM178) and initiated a substantive review.

Astellas Pharma, Inc, has announced the receipt of a letter from the FDA indicating that it accepted for filing the new drug application for mirabegron (YM178) and initiated a substantive review.

Astellas is seeking approval for mirabegron for the indication of overactive bladder associated with symptoms of urgency, urinary frequency, and urge incontinence.

The target date for the review completion is June 29, 2012.A similar letter from the European Medicines Agency validating the application and confirming the start of the review procedure was also received, the company said.

Go back to this issue of Urology Times eNews.

Related Videos
Related Content
Pivotal data for lumasiran in PH1 published in NEJM
April 1st 2021

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
Nedosiran explored in primary hyperoxaluria type 3
February 26th 2021

Nedosiran explored in primary hyperoxaluria type 3

Jason M. Broderick
The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
February 9th 2021

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Jason M. Broderick
FDA new drug application filing expected by the end of 2021.
Site Logo
September 12th 2012

FDA approves androgen inhibitor for metastatic PCa

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).
Site Logo
August 29th 2012

Blood test could guide treatment for kidney cancer

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.
Site Logo
August 22nd 2012

BCG for bladder cancer in short supply

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.
© 2024 MJH Life Sciences

All rights reserved.